Navigation Links
YAG laser YC-1600

ProductsYAG laser YC-1600
Company NIDEK, Inc.
Item YAG laser YC-1600
Features Nd : YAG Laser (1064nm); Lightweight Model; Aiming Beam Rotation- (360 degrees continuous variable) Added to further enhance the accuracy; Wide Range Posterior/Anterior Focus Shift Mechanism; Focus Shift in 25 m Steps
Description The Nidek's ophthalmic Nd: YAG laser YC-1600 is a lightweight, compact, yet fully featured system of superb versatility and clinical performance.

Key Features

  • Nd : YAG Laser (1064nm)
  • Lightweight Model
    Further weight reduction has been made to realize more convenient setting in your office.
  • Aiming Beam Rotation
    (360 degrees continuous variable) Added to further enhance the accuracy.
  • Wide Range Posterior/Anterior Focus Shift Mechanism
    Offsets the focal point of the YAG energy, to avoid damage to the IOL. This is particularly important with existing IOL designs made from conventional PMMA material and the increasingly more popular Silicon materials.
  • Focus Shift in 25 m Steps
The system may be used as combination delivery system with Nidek DC-3300 or GYC-2000/1500 Green YAG Laser consoles.
Info NIDEK, Inc.
Customer Service: 1-800-223-9044
Web site: http://www.usa.nidek.com

Related medicine products :

1. Novus 2000 argon laser
2. Compact KTP laser
3. SmilePro 980 diode laser
4. StoneLight Holmium laser
5. G-4 goniolaser
TAG: YAG laser
...ut patients negative for antinuclear antibodies, w...c diseases such as Systemic lupus erythematosus (L...disease, progressive systemic sclerosis, scleroder...henomenon. They can also be used in conjunction wi...
The PANBIO Inc. Indirect Fluorescence Assay (IFA) for IgG Antinuclear Antibody (ANA) HEp2 is intended for the qualitative and semi-quantitative detection of IgG (Immunoglobulin G) antinuclear antibod
The VerifyNow Clopidogrel Assay measures changes in platelet function in response to patients taking Clopidogrel (Plavix). It uses a specific activator for the P2Y12 pathway, which clopidogrel inhibi
The Wide Angle Twin Mag NP combines the performance of two instruments to deliver unequalled power and versatility into the hands of eye care professionals.
Medicine Products:
(Date:7/25/2008)...SNewswire/ -- The following is being,issued by the...ww.newscom.com/cgi-bin/prnh/20080519/DNCLOGO ), M...on Disabilities, and,Bob Kafka, National Organizer...e of John McCain,s appearance via satellite at the...Ohio. There is speculation that Senator,McCain wil...
(Date:7/25/2008)...arter financial results -, LAVAL, QC, July 25 /PR...SDAQ: DDSS) today announced that it will host a co...) to discuss its second quarter 2008,financial res...8 financial,results via news release at approximat...ence call by telephone, dial 416-646-3095 or,1-800...
(Date:7/25/2008)...troviral therapy may be due to genetic factors , ...ew study challenges the long-held belief that the ...s ability to restore itself after HIV patients are... (HAART). , From 50 percent to 90 percent of HI...Intravenous drug use is the main cause of both typ...
(Date:7/25/2008)...e American Society for Gastrointestinal Endoscopy ...opy in the bariatric surgery patient. The rising p...success in surgical interventions led to a marked ...rformed in the U.S., from 13,365 in 1998 to 102,79... preoperative patient and the postoperative patien...
Breaking Medicine News(10 mins):Health News:AUDIO OF CONFERENCE CALL: National Disability Rights Leaders Dubious Over John McCain's Possible Switch on Community Choice Act, Says DNC 2Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3
...netary Fund (IMF) said that there would be a signi...had not set aside a plan of action against the avi...watchdog. It said that a pandemic would trigger sh...s commodities, tourism and trade would recede and ...
...ntists from Princeton University says that running...of exercising. The reserachers led by Elizabeth Go...science that running alone does not seem to genera...after running or exercising in pairs or in groups....
...ection for a zone in Torun, in northern Poland on ...ad swan was found. Polish vets confirmed the prese...he swan was found near the German border but the v...he bird had the potent strain that could infect hu...
...mbia and Maryland may stand to lose heavily in fed...cal health departments to record identities of peo... two jurisdictions figure among many in the countr...s using codes and not names. The Centers for Disea...
Other Medicine News:
(Date:7/24/2008)...July 24 /PRNewswire-USNewswire/ -- Headlines claim...he whole story. The small scale,preliminary study...n,Reproduction, is based on recollected intake of ...oods. "This study is confounded by many,issues, th...t deal of,caution," warned Dr. Tammy Hedlund, a re...
(Date:7/24/2008)...OLIS, France, July 24 /- Ni... top-line results from the 52-week,open label safe...letion of,the 301 phase 3 study for naproxcinod. T...and efficacy was maintained for the one-year durat...bal assessment scale. In,addition, the results sho...
(Date:7/23/2008)...July 23 /PRNewswire-USNewswire/ -- The following w...hairman Conyers, Ranking Member Smith, and Members...o testify today., Since I appeared before this Co...better acquainted with the talented and dedicated ...he work they do, and I have come to,appreciate tha...
(Date:7/23/2008)...y 23 /- Dendreon Corporatio... the Independent Data,Monitoring Committee (IDMC) ...overall survival relating to the Company,s Phase 3... Treatment, also known as D9902B) clinical trial,o...any,s investigational,active cellular immunotherap...
Breaking Medicine Technology:Soyfoods Do Not Impact Sperm Count 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Study finds circumcision safe in both HIV infected and HIV uninfected men 20907 1Study finds circumcision safe in both HIV infected and HIV uninfected men 20907 2Study finds circumcision safe in both HIV infected and HIV uninfected men 20907 3Chinese Officials Cancel Dog Cull in Earthquake Zone 20905 1Chinese Officials Cancel Dog Cull in Earthquake Zone 20905 2Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma 2298 1Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma 2298 2Oticon Tapes Out Innovative Hearing Aid DSP Using Synopsys IC Compiler 20903 1Oticon Tapes Out Innovative Hearing Aid DSP Using Synopsys IC Compiler 20903 2Oticon Tapes Out Innovative Hearing Aid DSP Using Synopsys IC Compiler 20903 3
... Profile and Excellent,Pharmacokinetic Properties ...RNewswire/ --,CeNeRx BioPharma, Inc., a clinical s...tive treatments for diseases of the central,nervou...Phase I,clinical trial of Tyrima(TM), its lead can.... In this study, Tyrima was safe and well,tolerate...
...7 /PRNewswire-FirstCall/ -- CV,Therapeutics, Inc. ...ogy (JACC) has published data from the Ranolazine ... long-term therapy with,Ranexa(R) (ranolazine exte...d in patients with chronic stable angina who compl...led in the ROLE,program. , These data also suggest...
Other Medicine Technology:CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 3JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 2JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 3JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 4